Australia rows back on biosimilar naming; waiting game continues in US
This article was originally published in SRA
Executive Summary
Having been among the first to adopt a distinct naming convention for biosimilars, the Australian Therapeutic Goods Administration has now put its policy on hold while the World Health Organization thrashes out its own guidelines for the naming of biologic and biosimilar products1.
You may also be interested in...
Australia Revives Debate Over Unique Suffixes For Biologic Medicines
The Australian medicines agency has launched a public consultation on whether specific naming requirements should be applied to biologicals and their biosimilar versions. Among the options are the use of bar codes and suffixes to ensure individual products can be identified for traceability and pharmacovigilance purposes.
Australia Revives Debate Over Unique Suffixes For Biologic Medicines
The Australian medicines agency has launched a public consultation on whether specific naming requirements should be applied to biologicals and their biosimilar versions. Among the options are the use of bar codes and suffixes to ensure individual products can be identified for traceability and pharmacovigilance purposes.
‘Close The R&D Gap’ Between EU & Other Regions, EFPIA Tells Lawmakers
As EU legislators begin their discussion of the EU pharmaceutical overhaul, EFPIA has issued its formal response to the proposals, with a focus on topics such as unmet medical need, environmental risk assessments and drug shortages.